Research
Hormonal
GLP-1 receptor agonists (GLP-1RA) are effective pharmacological interventions for obesity that work by binding to GLP-1 receptors to stimulate insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite.
GLP-1 receptor agonists are a key pharmacological tool for treating obesity. They work by mimicking a gut hormone to reduce appetite and improve metabolic function. Consult a doctor to see if this treatment is appropriate for you.
StrongSupportsHIGH confidence
GLP-1 is a peptide hormone... It binds to the GLP-1 receptor... Upon receptor activation, GLP-1 stimulates insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite.
Why this rating
Review of established pharmacological mechanisms.
Source
The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Gašper Tonin et al. · Obesity Reviews · 2025
DOI 10.1111/obr.13978
narrative_reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is fundamentally a chronic metabolic disease characterized by disturbances in energy homeostasis and excessive fat accumulation, driven by a complex interplay of genetic, epigenetic, biological, psychological, and environmental factors.Strong
- Genetic variants, particularly in the MC4R, FTO, and LEP/LEPR genes, significantly influence susceptibility to obesity, affecting appetite regulation, energy expenditure, and fat storage.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →